MX2011011333A - Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion. - Google Patents

Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion.

Info

Publication number
MX2011011333A
MX2011011333A MX2011011333A MX2011011333A MX2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A MX 2011011333 A MX2011011333 A MX 2011011333A
Authority
MX
Mexico
Prior art keywords
fluids
electrokinetically
altered
membrane
insulin resistance
Prior art date
Application number
MX2011011333A
Other languages
English (en)
Spanish (es)
Inventor
Anthony B Wood
Gregory J Archambeau
Richard L Watson
Original Assignee
Revalesio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revalesio Corp filed Critical Revalesio Corp
Publication of MX2011011333A publication Critical patent/MX2011011333A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2011011333A 2009-04-27 2010-04-27 Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion. MX2011011333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17313409P 2009-04-27 2009-04-27
PCT/US2010/032620 WO2010126908A1 (en) 2009-04-27 2010-04-27 Compositions and methods for treating insulin resistance and diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2011011333A true MX2011011333A (es) 2011-11-18

Family

ID=43032520

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011333A MX2011011333A (es) 2009-04-27 2010-04-27 Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion.

Country Status (9)

Country Link
EP (1) EP2424507A4 (ja)
JP (2) JP2012525396A (ja)
CN (1) CN102413817B (ja)
AU (1) AU2010241736B2 (ja)
BR (1) BRPI1013992A2 (ja)
CA (1) CA2758738A1 (ja)
IL (1) IL215925A0 (ja)
MX (1) MX2011011333A (ja)
WO (1) WO2010126908A1 (ja)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2007128721A1 (de) 2006-05-04 2007-11-15 Boehringer Ingelheim Internationalgmbh Polymorphe
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
CA2757037C (en) 2009-01-29 2019-08-06 Forsight Vision4, Inc. Posterior segment drug delivery
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AU2011285545B2 (en) 2010-08-05 2014-03-13 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
AU2011285548B2 (en) 2010-08-05 2014-02-06 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
HUE057267T2 (hu) 2010-08-05 2022-05-28 Forsight Vision4 Inc Berendezés szem kezelésére
US9492404B2 (en) 2010-08-12 2016-11-15 Revalesio Corporation Compositions and methods for treatment of taupathy
ES2777890T3 (es) * 2010-11-15 2020-08-06 Boehringer Ingelheim Int Terapia antidiabética vasoprotectora y cardioprotectora
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
CA2831606A1 (en) * 2011-04-13 2012-10-18 Revalesio Corporation Compositions and methods for inhibiting and/or modulating effector t-cells involved in inflammatory neurodegenerative disease
WO2013003620A2 (en) 2011-06-28 2013-01-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
ES2864203T3 (es) 2011-09-16 2021-10-13 Forsight Vision4 Inc Aparato de intercambio de fluido
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
JP6159584B2 (ja) * 2012-06-14 2017-07-05 松本　高明 輸液、輸液の製造方法および輸液装置
CH706747A2 (de) * 2012-07-17 2014-01-31 Hanspeter Steffen Verfahren zur Hydration, Straffung und Pflege der Haut, zur Behandlung von Dermatosen, Sonnenbrand und genereller Wunden mit Diamantelektroden hergestelltem Elektrolysewasser.
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP4302736A3 (en) 2013-03-28 2024-04-03 ForSight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
JP2016063804A (ja) * 2013-12-27 2016-04-28 亀井 一郎 ミトコンドリア活性化組成物
US20170056438A1 (en) * 2014-10-17 2017-03-02 Aqua Zest Corporation Nanobubble-containing composition and use thereof
KR102416726B1 (ko) 2014-07-15 2022-07-05 포사이트 비젼4, 인크. 안구 이식물 전달 디바이스 및 방법
WO2016022750A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN114587774A (zh) 2014-11-10 2022-06-07 弗赛特影像4股份有限公司 治疗眼睛的系统
JP6674748B2 (ja) * 2015-05-27 2020-04-01 花王株式会社 Ｇｌｐ−１分泌促進剤
AU2016355345A1 (en) 2015-11-20 2018-05-31 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
AR108177A1 (es) 2016-04-05 2018-07-25 Forsight Vision4 Inc Dispositivos de suministro de fármacos oculares implantables
CN105878194A (zh) * 2016-06-07 2016-08-24 沈阳药科大学 一种格列本脲纳米结晶制剂及其制备方法
CN106362166B (zh) * 2016-10-27 2019-12-10 武汉大学 肿瘤坏死因子受体相关泛支架和信号蛋白在治疗脂肪肝和ⅱ型糖尿病中的功能和应用
CA3082891A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
CN110006871A (zh) * 2019-02-20 2019-07-12 常州大学 一个基于外源性组胺检测的细胞模型以及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005792A1 (de) * 1990-10-02 1992-04-16 Buchholz Klaus L Verwendung eines reaktionsproduktes aus einem gas und einer flüssigkeit, sowie verfahren und vorrichtung zu seiner herstellung
US7196164B2 (en) * 1997-07-08 2007-03-27 Human Genome Sciences, Inc. Secreted protein HHTLF25
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
AU2002236795A1 (en) * 2001-02-01 2002-08-12 Hydron Technologies, Inc. Compositions and method of tissue superoxygenation
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
US7347944B2 (en) * 2005-06-03 2008-03-25 BAGLEY David Method for making and conditioning super-oxygenated and structured water
WO2008052145A2 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
EP2086668B1 (en) * 2006-10-25 2016-11-16 Revalesio Corporation Mixing device and method
US20080154795A1 (en) * 2006-12-25 2008-06-26 Amos Alon Auction platform and applications
JP2008156320A (ja) * 2006-12-26 2008-07-10 Hydrox Kk 抗酸化性機能水
WO2009055614A1 (en) * 2007-10-25 2009-04-30 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction
US20090227018A1 (en) * 2007-10-25 2009-09-10 Revalesio Corporation Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction

Also Published As

Publication number Publication date
CA2758738A1 (en) 2010-11-04
AU2010241736A1 (en) 2011-12-22
JP2015229678A (ja) 2015-12-21
BRPI1013992A2 (pt) 2016-08-16
EP2424507A1 (en) 2012-03-07
WO2010126908A1 (en) 2010-11-04
CN102413817B (zh) 2014-12-17
AU2010241736B2 (en) 2016-01-28
JP2012525396A (ja) 2012-10-22
CN102413817A (zh) 2012-04-11
EP2424507A4 (en) 2012-10-24
IL215925A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
MX2011011333A (es) Composiciones y metodos para tratar la resistencia a la insulina y la diabetes mellituscampo de la invencion.
MX337862B (es) Composiciones y métodos para el tratamiento de la esclerosis multiple.
WO2009134929A3 (en) Compositions and methods for treating digestive disorders
MX2010004554A (es) Composiciones y métodos para el tratamiento de inflamación.
MX2013001636A (es) Composiciones y metodos para el tratamiento de taupatias
EA201170601A1 (ru) Модуляторы регулятора трансмембранной проводимости при муковисцидозе
BR112014010275A2 (pt) formulações para tratamento de diabetes
BR112012031329A2 (pt) proteínas de fusão diméricas vstm3 e composições e métodos relacionados
ATE524482T1 (de) Ionische flüssigkeiten mit niedriger viskosität
BR112012014575A2 (pt) "uso combinado de proteínas cry1da e cry1fa para gerenciamento de resistência em inseto"
BRPI0810874A2 (pt) Líquido iônico, proceso para preparar um líquido iônico, e, uso de líquidos iônicos.
ATE548677T1 (de) Ionische flüssigkeit
BR112015013809A2 (pt) derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
BR112014018575A2 (pt) polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
BR112012006388A2 (pt) célula de vertebrado para produzir uma molécula, método para produzir uma molécula, molécula, composição, proteína ou lipídeo, unidade de expressão, célula eucariótica para produzir uma proteína, e, método para produzir uma proteína
WO2008027420A3 (en) Implantable devices for producing insulin
BR112012018374A2 (pt) derivados de ácido carboxílico de pirrolidina ou tiazolidina, composição farmacêutica e métodos para uso no tratamento de distúrbios metabólicos como agonistas de receptor 43 acoplado à proteína g (gpr43).
ATE458824T1 (de) Zellfreie in-vitro-transkription und translation von membranproteinen in gebundene planare lipidschichten
WO2011084711A3 (en) Hair growth methods using fgfr3 extracellular domains
GT201000119A (es) "procedimiento para la preparacion de una bebida fermentada"
ECSP066777A (es) Derivados de furosemida como moduladores de hm74 y su uso para el tratamiento de inflamacion
ITMI20080570A1 (it) Procedimento per la preparazione di polibutadiene ramificato ad alto contenuto in unita' 1,4-cis
ATE531703T1 (de) Benzochromenderivate
BR112015005055A2 (pt) sensores eletroquímicos e método para a fabricação dos mesmos

Legal Events

Date Code Title Description
FG Grant or registration